Cargando…
The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time
Exposure to the industrial solvent, styrene, induces locomotor and cognitive dysfunction in rats, and parkinsonian-like manifestations in man. The antipsychotic, haloperidol (HP), well known to induce striatal toxicity in man and animals, and styrene share a common metabolic pathway yielding p-fluor...
Autores principales: | , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089729/ https://www.ncbi.nlm.nih.gov/pubmed/20931367 http://dx.doi.org/10.1007/s12640-010-9222-y |
_version_ | 1782203073517584384 |
---|---|
author | Terre’Blanche, Gisella Heyer, Nicolette Bergh, Jacobus J. Mienie, Lodewyk J. van der Schyf, Cornelius J. Harvey, Brian H. |
author_facet | Terre’Blanche, Gisella Heyer, Nicolette Bergh, Jacobus J. Mienie, Lodewyk J. van der Schyf, Cornelius J. Harvey, Brian H. |
author_sort | Terre’Blanche, Gisella |
collection | PubMed |
description | Exposure to the industrial solvent, styrene, induces locomotor and cognitive dysfunction in rats, and parkinsonian-like manifestations in man. The antipsychotic, haloperidol (HP), well known to induce striatal toxicity in man and animals, and styrene share a common metabolic pathway yielding p-fluoro phenylglyoxylic acid and phenylglyoxylic acid (PGA), respectively. Using an exposure period of 30 days and the vacous chewing movement (VCM) model as an expression of striatal-motor toxicity, we found that incremental PGA dosing (220–400 mg/kg) significantly increased VCMs up to day 25, but decreased to control levels shortly after reaching maximum dose. However, a diminishing dose of PGA (400–200 mg/kg) did not evoke an immediate worsening of VCMs but precipitated a significant increase in VCMs following dosage reduction to 200 mg/kg on day 22. PGA exposure, therefore, compromises striatal-motor function that is especially sensitive to changes in exposure dose. Longer alternating dose exposure studies are needed to establish whether motor dysfunction is progressive in severity or longevity. These findings are of significance for the environmental toxicology of styrene in the chemical industry. |
format | Text |
id | pubmed-3089729 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-30897292011-06-06 The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time Terre’Blanche, Gisella Heyer, Nicolette Bergh, Jacobus J. Mienie, Lodewyk J. van der Schyf, Cornelius J. Harvey, Brian H. Neurotox Res Brief Communication Exposure to the industrial solvent, styrene, induces locomotor and cognitive dysfunction in rats, and parkinsonian-like manifestations in man. The antipsychotic, haloperidol (HP), well known to induce striatal toxicity in man and animals, and styrene share a common metabolic pathway yielding p-fluoro phenylglyoxylic acid and phenylglyoxylic acid (PGA), respectively. Using an exposure period of 30 days and the vacous chewing movement (VCM) model as an expression of striatal-motor toxicity, we found that incremental PGA dosing (220–400 mg/kg) significantly increased VCMs up to day 25, but decreased to control levels shortly after reaching maximum dose. However, a diminishing dose of PGA (400–200 mg/kg) did not evoke an immediate worsening of VCMs but precipitated a significant increase in VCMs following dosage reduction to 200 mg/kg on day 22. PGA exposure, therefore, compromises striatal-motor function that is especially sensitive to changes in exposure dose. Longer alternating dose exposure studies are needed to establish whether motor dysfunction is progressive in severity or longevity. These findings are of significance for the environmental toxicology of styrene in the chemical industry. Springer-Verlag 2010-10-08 2011 /pmc/articles/PMC3089729/ /pubmed/20931367 http://dx.doi.org/10.1007/s12640-010-9222-y Text en © The Author(s) 2010 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. |
spellingShingle | Brief Communication Terre’Blanche, Gisella Heyer, Nicolette Bergh, Jacobus J. Mienie, Lodewyk J. van der Schyf, Cornelius J. Harvey, Brian H. The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time |
title | The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time |
title_full | The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time |
title_fullStr | The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time |
title_full_unstemmed | The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time |
title_short | The Styrene Metabolite, Phenylglyoxylic Acid, Induces Striatal-Motor Toxicity in the Rat: Influence of Dose Escalation/Reduction over Time |
title_sort | styrene metabolite, phenylglyoxylic acid, induces striatal-motor toxicity in the rat: influence of dose escalation/reduction over time |
topic | Brief Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3089729/ https://www.ncbi.nlm.nih.gov/pubmed/20931367 http://dx.doi.org/10.1007/s12640-010-9222-y |
work_keys_str_mv | AT terreblanchegisella thestyrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT heyernicolette thestyrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT berghjacobusj thestyrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT mienielodewykj thestyrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT vanderschyfcorneliusj thestyrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT harveybrianh thestyrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT terreblanchegisella styrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT heyernicolette styrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT berghjacobusj styrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT mienielodewykj styrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT vanderschyfcorneliusj styrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime AT harveybrianh styrenemetabolitephenylglyoxylicacidinducesstriatalmotortoxicityintheratinfluenceofdoseescalationreductionovertime |